Patient characteristics
| Patient code . | Sex . | Age, y . | Paraprotein isotype . | Type of treatment . | Time between treatment and sample collection, mo . | Response at day 100/12 mo after treatment . | Duration of CR at time point of sample collection, mo . | GVHD at time point of sample collection . | Immuno-suppression at time point of sample collection . | Epitope polyreactivity . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MM031 | M | 50 | IgG λ | Allo-HSCT | 9 | CR/CR | 6 | No | No | 16 | ≥3* |
| MM043 | M | 54 | IgG κ | Allo-HSCT | 7 | CR/CR | 7 | No | CSA | 12 | |
| MM046 | F | 42 | IgA λ | Allo-HSCT | 18 | CR/CR | 15 | Skin | CSA | 9 | |
| MM041 | F | 41 | λ LC | Allo-HSCT | 16 | PR/CR | 12 | No | No | 6 | |
| MM025 | M | 65 | IgG κ | Allo-HSCT | 18 | PR/CR | 18 | No | No | 4 | |
| MM040 | M | 48 | IgG κ | Allo-HSCT | 18 | CR/CR | 20 | No | No | 4 | |
| MM054 | F | 61 | IgG κ | Allo-HSCT | 5 | CR/n.e. | 7 | No | CSA | 4 | |
| MM023 | M | 62 | IgG κ | Allo-HSCT | 5 | CR/CR | 1 | n.e. | n.e. | 3 | |
| MM045 | M | 55 | IgG λ | Allo-HSCT | 14 | CR/CR | 14 | No | No | 2 | <3* |
| MM047 | M | 51 | IgG λ | Allo-HSCT | 14 | vgPR/vgPR | — | No | No | 2 | |
| MM035 | M | 64 | IgA κ | Auto-HSCT | 14 | PR/PD | — | — | — | 2 | |
| MM077 | F | 57 | IgG κ | Auto-HSCT | 3 | vgPR/vgPR | — | — | — | 2 | |
| MM051 | M | 50 | IgG κ | Allo-HSCT | 18 | PR/PD | — | No | No | 1 | |
| MM064 | M | 65 | IgG κ | Auto-HSCT | 7 | PR/PR | — | — | — | 0 | |
| MM073 | M | 43 | κ LC | Bortezomib† | 3 | CR/CR | 4 | — | — | 0 | |
| MM074 | M | 61 | κ LC | Auto-HSCT | 28 | CR/PD | 25 | — | — | 0 | |
| MM075 | M | 73 | IgG λ | Auto-HSCT | 6 | CR/CR | 2 | — | — | 0 | |
| MM076 | F | 72 | κ LC | Auto-HSCT | 7 | CR/CR | 5 | — | — | 0 | |
| Patient code . | Sex . | Age, y . | Paraprotein isotype . | Type of treatment . | Time between treatment and sample collection, mo . | Response at day 100/12 mo after treatment . | Duration of CR at time point of sample collection, mo . | GVHD at time point of sample collection . | Immuno-suppression at time point of sample collection . | Epitope polyreactivity . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MM031 | M | 50 | IgG λ | Allo-HSCT | 9 | CR/CR | 6 | No | No | 16 | ≥3* |
| MM043 | M | 54 | IgG κ | Allo-HSCT | 7 | CR/CR | 7 | No | CSA | 12 | |
| MM046 | F | 42 | IgA λ | Allo-HSCT | 18 | CR/CR | 15 | Skin | CSA | 9 | |
| MM041 | F | 41 | λ LC | Allo-HSCT | 16 | PR/CR | 12 | No | No | 6 | |
| MM025 | M | 65 | IgG κ | Allo-HSCT | 18 | PR/CR | 18 | No | No | 4 | |
| MM040 | M | 48 | IgG κ | Allo-HSCT | 18 | CR/CR | 20 | No | No | 4 | |
| MM054 | F | 61 | IgG κ | Allo-HSCT | 5 | CR/n.e. | 7 | No | CSA | 4 | |
| MM023 | M | 62 | IgG κ | Allo-HSCT | 5 | CR/CR | 1 | n.e. | n.e. | 3 | |
| MM045 | M | 55 | IgG λ | Allo-HSCT | 14 | CR/CR | 14 | No | No | 2 | <3* |
| MM047 | M | 51 | IgG λ | Allo-HSCT | 14 | vgPR/vgPR | — | No | No | 2 | |
| MM035 | M | 64 | IgA κ | Auto-HSCT | 14 | PR/PD | — | — | — | 2 | |
| MM077 | F | 57 | IgG κ | Auto-HSCT | 3 | vgPR/vgPR | — | — | — | 2 | |
| MM051 | M | 50 | IgG κ | Allo-HSCT | 18 | PR/PD | — | No | No | 1 | |
| MM064 | M | 65 | IgG κ | Auto-HSCT | 7 | PR/PR | — | — | — | 0 | |
| MM073 | M | 43 | κ LC | Bortezomib† | 3 | CR/CR | 4 | — | — | 0 | |
| MM074 | M | 61 | κ LC | Auto-HSCT | 28 | CR/PD | 25 | — | — | 0 | |
| MM075 | M | 73 | IgG λ | Auto-HSCT | 6 | CR/CR | 2 | — | — | 0 | |
| MM076 | F | 72 | κ LC | Auto-HSCT | 7 | CR/CR | 5 | — | — | 0 | |
Allo-HSCT, allogeneic HSCT; Auto-HSCT, autologous HSCT; CR, complete remission; CSA, cyclosporine; F, female; GVHD, graft-versus-host disease; LC, light chain; M, male; n.e., not evaluable; PD, progressive disease; PR, partial response; vgPR, very good partial response.
Epitope reactivity and patients' responses revealed a significant association (chi-square test, P = .007). The χ2 testing was performed for time point 12 mo after HSCT.
Bortezomib-based therapy.